HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model.
暂无分享,去创建一个
R. Zabihollahi | F. Rahbarizadeh | K. Azadmanesh | M. Mahdavi | M. Ebtekar | M. Abolhassani | M. Yazdi | M. Ebtekar | Z. M. Hassan | H. Khorramkhorshid | Mehdi Mahdavi | Khorramkhorshid Hr | Fatemeh Rahbarizadeh | Rezvan Zabihollahi | Mohsen Abolhassani | Zuhair Muhammad Hassan
[1] Abbas Jamali,et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. , 2009, International immunology.
[2] B. Haynes,et al. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. , 2009, Vaccine.
[3] B. Ensoli,et al. Cross-clade immune responses to Gag p24 in patients infected with different HIV-1 subtypes and correlation with HLA class I and II alleles. , 2008, Vaccine.
[4] L. Thomsen,et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. , 2008, The Journal of general virology.
[5] B. Autran,et al. The Th1 immune response against HIV‐1 Gag p24‐derived peptides in mice expressing HLA‐A02.01 and HLA‐DR1 , 2007, European journal of immunology.
[6] G. Pantaleo,et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. , 2007, Vaccine.
[7] D. Birx,et al. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response , 2006, BMC Immunology.
[8] Bette T. Korber,et al. Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control , 2006, Journal of Virology.
[9] Shixia Wang,et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. , 2006, Virology.
[10] J. Mascola,et al. Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate , 2005, Journal of medical primatology.
[11] E. Sato,et al. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection , 2005, AIDS.
[12] R. Paranjape,et al. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. , 2005, The Journal of infectious diseases.
[13] Scott A. Brown,et al. Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. , 2005, Vaccine.
[14] A. Srinivasan,et al. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens. , 2005, Virology.
[15] M. Betts,et al. Prime-Boost Vaccination with HIV-1 Gag Protein and Cytosine Phosphate Guanosine Oligodeoxynucleotide, Followed by Adenovirus, Induces Sustained and Robust Humoral and Cellular Immune Responses 1 , 2003, Journal of Immunology.
[16] D. Strick,et al. Comprehensive Epitope Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T-Cell Responses Directed against the Entire Expressed HIV-1 Genome Demonstrate Broadly Directed Responses, but No Correlation to Viral Load , 2003, Journal of Virology.
[17] J. Shiver,et al. Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice. , 2002, Vaccine.
[18] M. Kuroda,et al. Potent CD4+ T Cell Responses Elicited by a Bicistronic HIV-1 DNA Vaccine Expressing gp120 and GM-CSF1 , 2002, The Journal of Immunology.
[19] S. Calarota,et al. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity. , 2001, Human gene therapy.
[20] J. Guillet,et al. DNA vaccination of macaques with several different Nef sequences induces multispecific T cell responses. , 2001, Virology.
[21] Todd M. Allen,et al. Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen1 , 2000, The Journal of Immunology.
[22] T. Kepler,et al. Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. , 1999, AIDS research and human retroviruses.
[23] H. Bukawa,et al. Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate. , 1997, Clinical immunology and immunopathology.
[24] C. Rinaldo,et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors , 1995, Journal of virology.